Previous 10 | Next 10 |
2024-03-25 17:59:24 ET More on Aerovate Therapeutics Seeking Alpha’s Quant Rating on Aerovate Therapeutics Historical earnings data for Aerovate Therapeutics Financial information for Aerovate Therapeutics Read the full article on Seeking Alpha ...
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Completed enrollment in the Phase 2b portion and enrolled first patient into the Phase 3 portion of the IMPAHCT trial of AV-10...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected curre...
2024-01-27 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-16 23:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-23 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company...
2023-11-13 13:38:58 ET More on Aerovate Therapeutics Seeking Alpha’s Quant Rating on Aerovate Therapeutics Historical earnings data for Aerovate Therapeutics Financial information for Aerovate Therapeutics For further details see: Aerovate Therapeu...
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the qua...
News, Short Squeeze, Breakout and More Instantly...
Aerovate Therapeutics Inc. Company Name:
AVTE Stock Symbol:
NASDAQ Market:
Aerovate Therapeutics Inc. Website:
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the I nhaled i M atinib P ulmonary A rterial H ypertension C linical T rial (IMPA...
A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 476.9% to $0.75 on volume of 1,104,730,765 shares NVIDIA Corporation (NVDA) fell 0.7% to $130.98 on volume of 283,604,651 shares ENDRA Life Sciences Inc. (NDRA) rose 34.2% to $0.139 on volume of 219,783,92...